Alnylam Pharmaceuticals
ALNY
$170.37
Share price
-1.45%
Change (1 day)
-24.68%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
P/S ratio for Alnylam Pharmaceuticals (ALNY)
P/S ratio as of December 2023 (TTM): 12.4
According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 12.4043. At the end of 2023 the company had a P/S ratio of 12.8.
P/S ratio history for Alnylam Pharmaceuticals from 2004 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 12.8 | -54.43% |
| 2022 | 28.2 | 17.32% |
| 2021 | 24.0 | -21.59% |
| 2020 | 30.6 | -47.89% |
| 2019 | 58.8 | -40.29% |
| 2018 | 98.5 | -29.73% |
| 2017 | 140 | 105.69% |
| 2016 | 68.1 | -65.05% |
| 2015 | 195 | 31.6% |
| 2014 | 148 | 70.45% |
| 2013 | 86.9 | 505.26% |
| 2012 | 14.4 | 241.19% |
| 2011 | 4.21 | 0.83% |
| 2010 | 4.17 | -43.09% |
| 2009 | 7.33 | -31.15% |
| 2008 | 10.7 | -54.28% |
| 2007 | 23.3 | -20.88% |
| 2006 | 29.4 | -34.68% |
| 2005 | 45.1 | 33.85% |
| 2004 | 33.7 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 3.81 | -69.29% | 🇨🇭 Switzerland |
 Sanofi SNY | 2.37 | -80.93% | 🇫🇷 France |
 Regeneron Pharmaceuticals REGN | 6.83 | -44.95% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | 7.46 | -39.84% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | N/A | N/A | 🇺🇸 USA |
 OPKO Health
OPK | 1.42 | -88.57% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 0.7384 | -94.05% | 🇮🇱 Israel |
 Arrowhead Pharmaceuticals
ARWR | 10.5 | -15.71% | 🇺🇸 USA |